Should I buy or sell Cara Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CARA shares. View CARA analyst ratings or view top-rated stocks .

What is Cara Therapeutics' stock price target for 2024?

4 brokerages have issued 1 year target prices for Cara Therapeutics' shares. Their CARA share price targets range from $2.50 to $25.00. On average, they expect the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 1,284.5% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts .

How have CARA shares performed in 2024?

Cara Therapeutics' stock was trading at $0.7430 at the start of the year. Since then, CARA shares have decreased by 5.2% and is now trading at $0.7042. View the best growth stocks for 2024 here .

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CARA earnings forecast .

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) announced its earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $2.34 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 122.10% and a negative net margin of 565.21%. During the same quarter in the prior year, the firm earned ($0.56) earnings per share.

What ETF holds Cara Therapeutics' stock?

Amplify Seymour Cannabis ETF holds 65,538 shares of CARA stock, representing 0.15% of its portfolio.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A) , Zynerba Pharmaceuticals (ZYNE) , Puma Biotechnology (PBYI) , GW Pharmaceuticals (GWPH) , Novavax (NVAX) , INSYS Therapeutics (INSY) , Fate Therapeutics (FATE) and Incyte (INCY) .

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CARA

Cara Therapeutics (CARA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CARA Stock Alerts

$0.69

-0.04 (-5.72%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.68
▼
$0.74
50-Day Range: $0.52
▼
$1.05
52-Week Range: $0.50
▼
$4.67

Volume: 363,035 shs
Average Volume: 667,607 shs
Market Capitalization: $37.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.75

Get Cara Therapeutics alerts:

Cara Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 1,284.5% Upside
$9.75 Price Target
Short Interest: Bearish
5.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.39
Upright™ Environmental Score
News Sentiment: 0.56
Based on 9 Articles This Week
Insider Trading: Selling Shares
$30,906 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.03) to ($0.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

197th out of 914 stocks

Pharmaceutical Preparations Industry

71st out of 417 stocks

3.4

Analyst's Opinion

Consensus Rating
Cara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Cara Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.56% of the float of Cara Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cara Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cara Therapeutics has recently increased by 4.03%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cara Therapeutics does not currently pay a dividend.
Dividend Growth
Cara Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.
Environmental Sustainability
The Environmental Impact score for Cara Therapeutics is -1.39.

2.0

News and Social Media Coverage

News Sentiment
Cara Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 9 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,906.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Cara Therapeutics is held by insiders.
Percentage Held by Institutions
44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cara Therapeutics are expected to grow in the coming year, from ($1.03) to ($0.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cara Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cara Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cara Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cara Therapeutics Stock (NASDAQ:CARA)

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

CARA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CARA Stock News Headlines

April 15, 2024 | americanbankingnews.com

Cara Therapeutics, Inc. (NASDAQ:CARA) Expected to Earn FY2028 Earnings of ($0.21) Per Share

April 14, 2024 | msn.com

The Challenge: Zach Nichols reacts to seeing Cara Maria Sorbello back for All Stars 4

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 14, 2024 | msn.com

The Challenge’s Cara Maria Sorbello thought All Stars 4 castmates would reunite due to ‘hatred’ of her

April 14, 2024 | msn.com

NY GOP moves to knock ‘The Biggest Loser’ trainer Cara Castronuova out of Senate primary

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment

April 11, 2024 | investing.com

Cara Therapeutics CMO sells shares worth over $2,000

April 11, 2024 | americanbankingnews.com

Cara Therapeutics' (CARA) "Buy" Rating Reaffirmed at Needham & Company LLC

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential

April 9, 2024 | americanbankingnews.com

Cara Therapeutics (NASDAQ:CARA) Shares Cross Above 50 Day Moving Average of $0.79

April 2, 2024 | news.yahoo.com

Ashland Police Chief Cara Rossi reinstated today after two months of administrative leave

April 2, 2024 | msn.com

‘The Biggest Loser’ trainer Cara Castronuova sues NY GOP in bid for Senate

April 2, 2024 | globenewswire.com

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 30, 2024 | yahoo.com

Cara Delevingne’s First Song is Really (Really!) Good: Listen Here

March 30, 2024 | yahoo.com

Cara Delevingne Wears Trendy Pointy Shoes Out in London

March 29, 2024 | yahoo.com

Cara Delevingne Just Stepped Out in the Prettiest Hairstyle for Dior’s PFW Show

March 28, 2024 | markets.businessinsider.com

Demystifying Cara Therapeutics: Insights From 4 Analyst Reviews

March 17, 2024 | msn.com

Cara Delevingne thanks firefighters after cats rescued from her burning home

March 17, 2024 | msn.com

Cara Delevingne's Parents Spoke Out About The Heartbreaking Fire That Destroyed Her Home

March 17, 2024 | msn.com

Cara Delevingne’s Parents Reveal Probable Cause of Devastating Los Angeles House Fire

March 16, 2024 | finance.yahoo.com

CARA Apr 2024 5.000 call

March 15, 2024 | yahoo.com

Cara Delevingne says her 'heart is broken' after massive fire destroys California home

March 15, 2024 | msn.com

Cara Delevingne's Parents Reveal Cause of Her Devastating Los Angeles House Fire

March 15, 2024 | msn.com

Cara Delevingne’s parents say daughter is ‘devastated’ after LA mansion burned down, reveal cause of fire

March 15, 2024 | nbcnews.com

Cara Delevingne's California home destroyed by massive fire

March 15, 2024 | msn.com

Cara Delevingne’s L.A. Home Destroyed in Massive Fire in Middle of the Night: “My Heart is Broken”

See More Headlines

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CARA
CUSIP: N/A
CIK: 1346830
Web: www.caratherapeutics.com
Phone: (203) 406-3700
Fax: 203-567-1510
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.75
High Stock Price Target: $25.00
Low Stock Price Target: $2.50
Potential Upside/Downside: +1,232.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-118,510,000.00
Net Margins: -565.21%
Pretax Margin: -565.21%
Return on Equity: -122.10%
Return on Assets: -89.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.54
Quick Ratio: 4.43

Sales & Book Value

Annual Sales: $20.97 million
Price / Sales: 1.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.05 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 54,660,000
Free Float: 52,360,000
Market Cap: $40.01 million
Optionable: Optionable
Beta: 0.70

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Christopher A. Posner (Age 54)
President, CEO & Director
Comp: $1.2M
Mr. Ryan D. Maynard (Age 55)
Chief Financial Officer
Comp: $511.7k
Dr. Joana Goncalves M.D. (Age 50)
Chief Medical Officer
Comp: $747.25k
Dr. Derek T. Chalmers D.Sc. (Age 60)
Ph.D., Co-Founder & Senior Advisor
Comp: $580.93k
Dr. Iris Francesconi Ph.D.
Chief Strategy Officer & Head of Investor Relations
Mr. Scott M. Terrillion (Age 61)
Chief Compliance Officer, General Counsel & Corporate Secretary
Comp: $689.63k
Ms. Beth Weinberg R.Ph.
Senior Vice President of Regulatory Affairs & QA
Mr. Matthew Murphy
Manager of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CARA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.
What is Cara Therapeutics' stock price target for 2024?: 4 brokerages have issued 1 year target prices for Cara Therapeutics' shares. Their CARA share price targets range from $2.50 to $25.00. On average, they expect the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 1,284.5% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.
How have CARA shares performed in 2024?: Cara Therapeutics' stock was trading at $0.7430 at the start of the year. Since then, CARA shares have decreased by 5.2% and is now trading at $0.7042.
View the best growth stocks for 2024 here.
When is Cara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CARA earnings forecast.

How were Cara Therapeutics' earnings last quarter?: Cara Therapeutics, Inc. (NASDAQ:CARA) announced its earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $2.34 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 122.10% and a negative net margin of 565.21%. During the same quarter in the prior year, the firm earned ($0.56) earnings per share.
What ETF holds Cara Therapeutics' stock?: Amplify Seymour Cannabis ETF holds 65,538 shares of CARA stock, representing 0.15% of its portfolio.
What other stocks do shareholders of Cara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).
How do I buy shares of Cara Therapeutics?: Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CARA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cara Therapeutics (CARA) Stock Price, News & Analysis

Cara Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cara Therapeutics Stock (NASDAQ:CARA)

CARA Stock Price History

CARA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CARA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™